Tenax Therapeutics Inc. (NASDAQ:TENX) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tenax Therapeutics Inc.||1||0.00||N/A||-7.65||0.00|
|Adaptive Biotechnologies Corporation||39||90.57||N/A||-0.44||0.00|
Table 1 demonstrates Tenax Therapeutics Inc. and Adaptive Biotechnologies Corporation’s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows us the return on equity, net margins and return on assets of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Tenax Therapeutics Inc.||0.00%||-175.2%||-156.5%|
|Adaptive Biotechnologies Corporation||0.00%||0%||0%|
Tenax Therapeutics Inc.’s Current Ratio is 11 while its Quick Ratio is 11. On the competitive side is, Adaptive Biotechnologies Corporation which has a 7.3 Current Ratio and a 7.1 Quick Ratio. Tenax Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Adaptive Biotechnologies Corporation.
Institutional & Insider Ownership
Tenax Therapeutics Inc. and Adaptive Biotechnologies Corporation has shares owned by institutional investors as follows: 22.2% and 46.2%. About 4.73% of Tenax Therapeutics Inc.’s share are owned by insiders. Comparatively, Adaptive Biotechnologies Corporation has 4.7% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Tenax Therapeutics Inc.||-2.96%||-6.43%||-21.56%||11.97%||-79.3%||8.26%|
|Adaptive Biotechnologies Corporation||-4.53%||-3.87%||0%||0%||0%||-4.34%|
For the past year Tenax Therapeutics Inc. had bullish trend while Adaptive Biotechnologies Corporation had bearish trend.
On 5 of the 7 factors Adaptive Biotechnologies Corporation beats Tenax Therapeutics Inc.
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.